The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Epithelioid GBMs Show a High Percentage of BRAF V600E Mutation
Open accessAbstract
BRAF V600E mutation has been identified in up to 2/3 of pleomorphic xanthoastrocytomas (PXAs), World Health Organization grade II, as well as in varying percentages of PXAs with anaplastic features (PXA-A), gangliogliomas, extracerebellar pilocytic astrocytomas, and, rarely, giant cell glioblastoma multiforme (GC-GBMs). GC-GBMs and epithelioid GBMs (E-GBMs) can be histologically challenging to distinguish from PXA-A. We undertook this study specifically to address whether these 2 tumor types also showed the mutation. We tested our originally reported cohort of 8 E-GBMs and 2 rhabdoid GBMs (R-GBM) as well as 5 new E-GBMs (1 pediatric, 4 adult) and 9 GC-GBMs (2 pediatric, 7 adult) (n=24) for BRAF V600E mutational status. Twenty-one of 24 had sufficient material for IDH-1 immunostaining, which is usually absent in PXAs, PXA-As, and primary GBMs but present in secondary GBMs. Patients ranged in age from 4 to 67 years. BRAF V600E mutation was identified in 7/13 of E-GBMs, including 3 of our original cases; patients with mutation were aged 10 to 50 years. None of the 9 GC-GBMs or 2 R-GBMs manifested this mutation, including pediatric patients. The sole secondary E-GBM was the single case manifesting positive IDH-1 immunoreactivity. A high percentage of E-GBMs manifest BRAF V600E mutation, paralleling PXAs. All R-GBMs and GC-GBMs were negative, although larger multi-institutional cohorts will have to be tested to extend this result. BRAF V600E mutational analyses should be performed on E-GBMs, particularly in all pediatric and young-aged adults, given the potential for BRAF inhibitor therapy in this subset of GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
Schindler, G., Capper, D., Meyer, J., Janzarik, W., Omran, H., Herold-Mende, C., Schmieder, K., Wesseling, P., Mawrin, C., Hasselblatt, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0802-6 · Cited by 1,034
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
Capper, D., Weißert, S., Balss, J., Habel, A., Meyer, J., Jäger, D., Ackermann, U., Tessmer, C., Korshunov, A., Zentgraf, H., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00352.x · Cited by 526
Kepes, J. J., Rubinstein, L. J., & Eng, L. F. (1979) · Cancer · doi:10.1002/1097-0142(197911)44:5<1839::aid-cncr2820440543>3.0.co;2-0 · Cited by 481
Menzies, A. M., Haydu, L. E., Visintin, L., Carlino, M. S., Howle, J. R., Thompson, J. F., Kefford, R. F., Scolyer, R. A., & Long, G. V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0052 · Cited by 434
Pleomorphic xanthoastrocytoma: What do we really know about it?
Giannini, C., Scheithauer, B. W., Burger, P. C., Brat, D. J., Wollan, P. C., Lach, B., & O'Neill, B. P. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9<2033::aid-cncr22>3.0.co;2-z · Cited by 335
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas
Dougherty, M. J., Santi, M., Brose, M. S., Ma, C., Resnick, A. C., Sievert, A. J., Storm, P. B., & Biegel, J. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq007 · Cited by 324
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
(1997) · PubMed · Cited by 256
Targeted Therapy for BRAFV600E Malignant Astrocytoma
Nicolaides, T. P., Li, H., Solomon, D. A., Hariono, S., Hashizume, R., Barkovich, K. J., Baker, S. J., Paugh, B. S., Jones, C., Forshew, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1456 · Cited by 154
Kepes, J. J., Rubinstein, L. J., Ansbacher, L. E., & Schreiber, D. J. (1989) · Acta Neuropathologica · doi:10.1007/bf00691285 · Cited by 110
Marton, E., Feletti, A., Orvieto, E., & Longatti, P. (2007) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2006.11.008 · Cited by 106
Pahapill, P. A., Ramsay, D. A., & Maestro, R. F. D. (1996) · Neurosurgery · doi:10.1097/00006123-199604000-00038 · Cited by 103
Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma
Rodríguez, F. J., Scheithauer, B. W., Giannini, C., Bryant, S. C., & Jenkins, R. B. (2008) · Cancer · doi:10.1002/cncr.23899 · Cited by 92
The Lipid-Rich Epithelioid Glioblastorna
Rosenblum, M. K., Erlandson, R. A., & Budzilovich, G. N. (1991) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199110000-00002 · Cited by 63
Kaulich, K., Blaschke, B., Nümann, A., von Deimling, A., Wiestler, O. D., Weber, R. G., & Reifenberger, G. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.12.1092 · Cited by 63
Pleomorphic xanthoastrocytoma: report of two cases and review of the prognostic factors
Tan, T., Ho, L., Yu, C.-P., & Cheung, F. (2003) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2003.04.003 · Cited by 28
Epithelioid glioblastoma: a case report
Akimoto, J., Namatame, H., Haraoka, J., & Kudo, M. (2005) · Brain Tumor Pathology · doi:10.1007/s10014-005-0173-6 · Cited by 19
Cited by
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Management of glioblastoma: State of the art and future directions
Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21613 · Cited by 1,972
Glioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
WHO 2016 Classification of gliomas
Wesseling, P., & Capper, D. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12432 · Cited by 795
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Metadata
- Authors
- Kleinschmidt-DeMasters, B. K., Aisner, D. L., Birks, D. K., & Foreman, N. K.
- Venue
- American Journal of Surgical Pathology
- Published
- 2013-05
- Volume
- 37
- Issue
- 5
- Pages
- 685-698
- ISSN
- 0147-5185 (ISSN-L)
- OpenAlex
- W2122004774
- Cited by
- 260
- References
- 22
- FWCI
- 9.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.